Does a Copper IUD Increase Your Risk of Cancer?

Copper IUDs do not increase cancer risk. The accumulated evidence across multiple cancer types actually points in the opposite direction: research consistently links copper IUD use with a reduced incidence of several gynecologic cancers, including endometrial, cervical, and ovarian cancer. The fear that a copper-releasing device sitting inside the uterus could promote malignancy is understandable but not supported by the data. What the data show is more surprising and far more reassuring than most people expect.

Endometrial Cancer and the Strongest Protective Signal

The most robust evidence for a cancer-protective effect involves endometrial cancer, the most common gynecologic malignancy. A 2023 expert review in the American Journal of Obstetrics and Gynecology concluded that both copper IUDs and hormonal IUDs reduce endometrial cancer risk, with the protective mechanism likely involving a combination of local inflammation and suppression of endometrial growth.¹ That local inflammatory response is not the harmful kind you might associate with infection. It appears to create an environment in the uterine lining that discourages the type of uncontrolled cell growth that leads to cancer.

A meta-analysis looking specifically at IUD use and endometrial cancer risk found that the protective effect grows with time. For every five years of IUD use, risk dropped further, and the benefit persisted even years after the device was removed.² That lingering benefit is worth noting because it suggests the copper IUD changes the uterine environment in ways that outlast the device itself.

At the cellular level, researchers have documented what happens to the endometrium during copper IUD use. One study measured cell division rates and hormone receptor levels in women before and after six months with a copper IUD. The rate of cell division in the uterine lining dropped sharply, and estrogen receptor levels fell substantially in both the glands and the tissue between them.³ Since estrogen-driven proliferation is one of the main pathways to endometrial cancer, that reduction in both cell turnover and estrogen sensitivity helps explain the protective signal seen in larger population studies.

Cervical Cancer and HPV

Cervical cancer is caused by persistent infection with high-risk strains of human papillomavirus, so any connection between copper IUDs and cervical cancer has to work through that viral pathway. The reassuring finding is that copper IUDs do not appear to increase HPV infection rates or make existing infections harder to clear. One prospective study found no link between IUD use and either acquiring or clearing HPV after adjusting for behavioral factors like new sexual partners, condom use, and smoking.⁴ A cross-sectional study comparing copper IUD users to women using no contraception found no difference in the rate of high-risk HPV or in high-grade cervical abnormalities.⁵

There is actually some evidence that copper IUDs may have a slight protective edge. A pooled analysis of studies found that copper IUD use was associated with a lower risk of advanced precancerous cervical lesions, though the result did not quite reach the threshold of statistical certainty.⁶ A direct comparison between copper IUD users and hormonal IUD users was more striking: copper IUD users had a much lower rate of high-grade cervical abnormalities, with roughly a third the risk compared to levonorgestrel IUD users.⁷ Researchers are not entirely sure why the copper IUD might outperform the hormonal IUD on this front. One theory is that the local immune activation triggered by copper helps the body fight off HPV-infected cells, but that remains speculative.

The practical takeaway for cervical cancer is clear: a copper IUD does not put you at greater risk of HPV infection or cervical abnormalities, and it may modestly help. That said, it is not a substitute for cervical screening or HPV vaccination.

Ovarian Cancer

Ovarian cancer is rarer than endometrial or cervical cancer, and the data on IUDs and ovarian cancer are thinner and somewhat mixed. A systematic review and meta-analysis pooling the available retrospective studies found that women who had ever used an IUD had about a third lower risk of developing ovarian cancer compared to never-users.⁸ That is a substantial reduction, and it aligns with the general pattern seen across gynecologic cancers.

The picture gets more complicated when you look at specific patterns of use. A large case-control study found no overall association between any IUD type and ovarian cancer. However, it did observe a curious trend: among women who had used an IUD, those who started using one at age 35 or older had a higher ovarian cancer risk than those who started before 25.⁹ This does not mean that starting an IUD later causes ovarian cancer. It may reflect confounding factors, such as the reason a woman chose an IUD later in life, or differences in reproductive history that independently affect ovarian cancer risk. The 2023 expert review noted that while study results conflict, most data lean toward a reduced risk for IUD users.¹

The mechanism behind any ovarian protection is not well understood. Some researchers have proposed that the inflammatory response in the uterus could travel through the fallopian tubes and alter the environment around the ovaries. Others point out that the IUD string passing through the cervix might function as a physical barrier that subtly changes the passage of cells or pathogens upward. These ideas remain theoretical.

Breast Cancer

Breast cancer is the most common cancer in women worldwide, and any contraceptive method that raised breast cancer risk would be a serious concern. Hormonal contraceptives, including some hormonal IUDs, have drawn scrutiny on this front because they deliver progestins that can influence breast tissue. The copper IUD, which releases no hormones, sidesteps that concern entirely.

A large study using cancer registries in Finland and Germany compared breast cancer rates between users of the hormonal levonorgestrel IUD and users of the copper IUD. Across more than 5,000 breast cancer cases and 20,000 matched controls, the two groups had virtually identical breast cancer rates. There was no increased risk associated with either device, regardless of how long women had used them, how recently they had used them, or what age they were.¹⁰ The copper IUD served as the reference group in this analysis, meaning it was treated as the baseline. Finding no difference between the two types suggests neither carries a meaningful breast cancer risk.¹¹

For women specifically worried about breast cancer, the copper IUD is about as neutral a contraceptive choice as exists. It delivers no systemic hormones, and the research that exists shows no signal of harm.

Why Would Copper Protect Against Cancer?

The proposed mechanisms are local, not systemic. A copper IUD sits inside the uterus and continuously releases tiny amounts of copper ions into the surrounding tissue. Those ions trigger a chronic, low-grade inflammatory response in the endometrium. That sounds alarming if you associate inflammation with disease, but the effect here seems to work differently from the kind of chronic inflammation linked to cancer risk in other organs.

The copper-driven inflammation attracts immune cells into the uterine lining, including white blood cells that patrol for abnormal cells. Researchers have characterized this as a sterile (non-infectious) inflammatory state that may enhance immune surveillance without the tissue damage you see with persistent infections.¹² At the same time, copper ions suppress endometrial cell proliferation and reduce the tissue’s sensitivity to estrogen, as shown by the drops in mitotic activity and estrogen receptor concentrations documented in biopsy studies.³ Cells that divide less frequently and respond less vigorously to growth signals are, in simple terms, less likely to accumulate the mutations that lead to cancer.

Copper ions also participate in reactions that generate reactive oxygen species, which are molecules capable of damaging DNA and killing cells. In laboratory settings, researchers have studied how elevated copper inside cells ramps up oxidative stress.¹³ At the low concentrations released by an IUD, this effect appears to selectively discourage the survival of rapidly dividing cells rather than harming healthy tissue. The same property that makes copper toxic to sperm (the IUD’s primary contraceptive function) may contribute to its anti-proliferative effect on endometrial cells.

The Copper-in-Blood Concern

A common worry is that a device releasing copper inside the body could raise copper levels in the blood and potentially cause harm, including cancer risk. Copper is an essential trace element, but in excess it can be toxic. So what does the evidence show?

A literature review looking at twelve studies on blood copper levels in copper IUD users found conflicting results. Eight studies showed no increase in blood copper levels during IUD use, while four showed a significant rise.¹⁴ One of those studies, conducted in Mexico, found that IUD users had blood copper levels roughly double those of non-users, which was above the normal reference range.¹⁵

Before that triggers alarm, some context matters. The review noted that all the studies measured total copper in the blood, not free copper. Most copper in the blood is bound to proteins and is biologically inactive. Free copper is the form that can cause oxidative damage to tissues, and none of the studies assessed it. This makes it genuinely difficult to say whether the elevated total copper readings in some studies have any clinical significance. The amount of copper released by a standard IUD like the T380A is measured in micrograms per day, which is a fraction of the copper most people consume through food and water. Dietary copper intake for adults typically ranges from about 1,000 to 1,600 micrograms per day, while the IUD releases roughly 50 to 80 micrograms per day.

There is no evidence linking the copper released by an IUD to any systemic cancer. The anti-cancer effects described in the research are local, happening right where the copper contacts the uterine lining, and the amounts involved are too small to meaningfully shift whole-body copper metabolism for most women. That said, the inconsistent findings on blood levels mean this remains an area where better studies, measuring free rather than total copper, would be welcome.

Does Duration of Use Matter?

For endometrial cancer, yes. The meta-analysis of IUD use and endometrial cancer found a dose-response relationship: the longer a woman used an IUD, the lower her risk. Each additional five years of use was associated with a further drop in endometrial cancer incidence.² The protective effect also persisted after the device was removed, with a gradual attenuation over time. Women who had last used an IUD many years earlier still showed some residual benefit compared to women who had never used one.

For cervical and ovarian cancer, the data on duration are less definitive. Most studies compare “ever used” versus “never used” rather than parsing years of use, partly because sample sizes become small when you break down already uncommon outcomes by duration. The available evidence does not suggest that longer use reverses the protective signal for any cancer type. In other words, keeping a copper IUD in for its full approved lifespan of ten to twelve years does not appear to introduce late-emerging cancer risks.

Common Misconceptions About Copper IUDs and Cancer

One persistent myth is that a foreign object sitting in the uterus for years could irritate the tissue and cause cancer, the way chronic irritation is linked to cancer in some other organs. While chronic irritation can indeed promote cancer in certain contexts (chronic acid reflux and esophageal cancer, for instance), the inflammatory response provoked by a copper IUD behaves differently. It does not cause the kind of sustained tissue damage and repair cycling that drives malignant transformation. Instead, it appears to suppress proliferation, which is the opposite of what you would need for cancer to develop.¹²

Another misconception is that because copper can generate harmful reactive oxygen species in laboratory experiments, it must be causing DNA damage inside the body. But the dose and context matter enormously. The controlled, low-level release of copper from an IUD is fundamentally different from flooding isolated cancer cells with copper compounds in a lab dish. Inside the uterus, the copper concentrations involved are enough to create an inhospitable environment for sperm and to modestly shift the balance of cell growth, but they are not high enough to act as a carcinogen.

A third misconception conflates copper IUDs with hormonal IUDs. Hormonal IUDs release levonorgestrel, a synthetic progestin, and the cancer-risk profile for hormonal contraception is a separate and more complex discussion. When people hear that “IUDs may affect cancer risk,” they sometimes lump all IUDs together. The copper IUD’s story is distinct: no hormones, no systemic drug exposure, and a mechanism of action that is entirely local. Any discussion of IUD-related cancer risk needs to specify which type of IUD is being discussed, because the underlying biology is completely different.

Who Should Pay Attention to This Research

Women choosing a contraceptive method and weighing long-term safety can be reassured that copper IUDs carry no established cancer risk and may confer meaningful protection against endometrial cancer in particular. If cancer risk is a factor in your contraceptive decision, the copper IUD is one of the most favorable options available. It offers strong contraceptive efficacy, lasts a decade or more, and the side-effect profile (primarily heavier periods and more cramping, especially in the first few months) is well characterized.

Women with a family history of endometrial or ovarian cancer sometimes ask whether the copper IUD could offer a secondary benefit beyond contraception. The research is observational rather than from randomized trials, so no medical organization currently recommends copper IUDs specifically for cancer prevention. But the signal is consistent enough that it is a reasonable topic to raise with a gynecologist, particularly for women who would benefit from long-acting contraception anyway.

Women with Wilson’s disease, a rare genetic condition that impairs the body’s ability to process copper, are generally advised to avoid copper IUDs regardless of cancer considerations. For everyone else, the evidence paints a remarkably consistent picture: a device that was designed purely for contraception appears, as a side benefit, to create an environment in the uterus that makes cancer less likely to take hold.

1
PubMed. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review
2
PubMed. Meta-analysis of intrauterine device use and risk of endometrial cancer
3
PubMed. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu-T prevent endometrial cancer?
4
PubMed Central. The Effect of Intrauterine Devices on Acquisition and Clearance of Human Papillomavirus
5
PubMed. Prevalence of high-risk HPV and cervical dysplasia in IUD users and controls: a cross sectional study
6
PubMed Central. Intrauterine device use and the risk of precancerous cervical lesions and cervical cancer
7
PubMed Central. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users
8
Obstetrics & Gynecology. Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis
9
PubMed Central. Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses’ Health Studies
10
PubMed. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer
11
PubMed Central. Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk
12
Reproductive and Developmental Medicine. Effects of Copper-Containing Intrauterine Devices on the Endometrium
13
Bioconjugate Chemistry. Copper(II) Cyclopeptides with High ROS-Mediated Cytotoxicity
14
PubMed. A Literature Review of the Effects of Copper Intrauterine Devices on Blood Copper Levels in Humans
15
PubMed. Blood copper levels in Mexican users of the T380A IUD